Healthcare Industry News: PHOENIX
News Release - November 9, 2006
Amicus Acquires Houston Hyperbaric Center
LUBBOCK, Texas--(HSMN NewsFeed)--Amicus Hyperbaric Group, LLC ("Amicus") today announced that it has acquired Southcoast Hyperbarics and Wound Care Center in Houston. Amicus said that the Southcoast Center will provide hyperbaric services to Texas Specialty Hospital under an exclusive long-term contract.Don Sprague, M.D., formerly Medical Director (through Kelsey Seybold) at the Johnson Space Center at NASA, will serve as Medical Director of the Southcoast Center and Jay Rain, formerly Clinical Research Specialist with Surgical and Infectious Disease and Hyperbaric/Woundcare Medical Team at UTMB - Galveston will serve as Chief Technologist.
"Acquisition of the Southcoast center is a first step in our multi-phase plan to provide the Greater Houston Metropolitan Area with quality hyperbaric and wound care services," said Jim Bullard, Amicus' President. "We are particularly pleased that Don and Jay will oversee its operations as both are highly qualified practitioners in this critical field,"
Acquisition of the center is part of Amicus' overall plan to establish hyperbaric centers throughout the southwestern United States to provide needed treatment for diabetic or geriatric wounds. Hyperbaric therapy is a Medicare-approved therapy to treat wounds in diabetic and other patients. The majority of hyperbaric services is directed to the treatment of diabetic foot wounds or wounds indirectly related to diabetes.
Amicus Hyperbaric Group, LLC was founded in 2003 to provide hyperbaric services to hospitals throughout the United States. Amicus, one of the largest providers of hyperbaric therapy services in Texas, has operations in Amarillo, Abilene, Houston, Lubbock, McAllen (two hospitals), Fort Worth, Floresville (a suburb of San Antonio), Odessa and PHOENIX, Arizona. More information on Amicus is available on our website: www.amicusO2.com.
Source: Amicus Hyperbaric Group
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
